# Virobay

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/virobay

- Industry: Pharmaceuticals
- Headquarters: Menlo Park, US
- Website: www.virobayinc.com
- Total disclosed funding: $23M
- Latest round: Series B (Jul 29, 2014)
- Investors on record: 5

## About

Virobay Inc. is a biopharmaceutical company focused on developing innovative protease inhibitors to treat various diseases, including autoimmune disorders and cancer, employing a virtual model for drug discovery.Founded in 2006 and headquartered in Menlo Park, US, Virobay Inc. specializes in designing protease inhibitors. The company has not undergone significant pivots in its business strategy. Virobay was established through the efforts of industry professionals; however, specific founder details are not available. To date, Virobay has completed five funding deals, with the most recent being a Series B round in July 2014, which raised USD 8.000 mn from investors such as AbbVie Biotech Ventures and Alta Partners. Currently, Virobay is valued at USD 28.317 mn.Virobay, Inc. specializes in the design and development of protease inhibitors, primarily targeting autoimmune diseases, neuropathic pain, liver diseases, and cancer. Their lead compounds, including VBY-036 and VBY-891, are under clinical development with specific applications for the treatment of neuropathic pain and oral psoriasis, respectively. VBY-036 commenced its Phase 1 Trial in 2013, while VBY-891 is being developed in collaboration with LEO Pharma. The company employs a virtual model for drug discovery, leveraging both in-house expertise and external contract research and manufacturing resources to ensure efficient and cost-effective development. Virobay's products aim to serve a diverse client base, including pharmaceutical companies and healthcare providers, primarily in North America and Europe.Virobay's revenue model is predominantly structured around partnerships and collaborations with pharmaceutical companies, such as the multi-million dollar agreement with LEO Pharma for the development of psoriasis treatments. This model allows Virobay to generate funding through joint ventures and milestone payments tied to the progress of their drug compounds in clinical trials. Revenue is derived from contractual agreements related to research and development services, as well as potential royalties from future sales of developed products. The company's flagship products, namely VBY-036 and VBY-891, are central to these transactions, positioning Virobay as an attractive partner within the biopharmaceutical landscape.Looking ahead, Virobay plans to utilize the USD 8.000 mn raised in its recent Series B financing to support the clinical development of VBY-036 and VBY-891 while exploring new product opportunities. The company is also focused on expanding its market presence in North America and Europe, with potential collaborations targeting additional therapeutic areas slated for exploration by the end of 2025. These initiatives are part of Virobay's strategic vision to enhance its pipeline and establish itself as a key player in the biopharmaceutical sector.

## Funding rounds

- Series B, Jul 29, 2014, $8M — Alta Partners, Sutter Hill Ventures, TPG Biotech, AbbVie Ventures, Perceptive Advisors
- Series B, May 18, 2010, $10M — Alta Partners, Sutter Hill Ventures
- Series A, Aug 28, 2006, $5.5M — Alta Partners, Sutter Hill Ventures, TPG Biotech

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series B
- Sutter Hill Ventures (https://capitalatlas.ai/funds/sutter-hill-ventures) — Series A, Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series A, Series B
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B